Insulin resistance, characterised by a reduced response of insulin‐targeting tissues, is a key driver of many metabolic diseases, such as type 2 diabetes, atherosclerotic diseases, and metabolic dysfunction‐associated steatotic liver disease.1 The gene discussed is INS; the disease is metabolic disease.